Perrigo Company (NYSE:PRGO) has been given a $93.00 target price by equities researchers at Cantor Fitzgerald in a report issued on Thursday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 40.12% from the company’s previous close.

PRGO has been the subject of several other reports. Wells Fargo & Company reiterated a “market perform” rating and set a $67.00 price objective on shares of Perrigo in a research note on Friday, April 14th. Deutsche Bank AG dropped their price objective on Perrigo from $87.00 to $86.00 and set a “buy” rating for the company in a research note on Wednesday, April 19th. B. Riley reiterated a “neutral” rating and set a $67.00 price objective on shares of Perrigo in a research note on Saturday, April 22nd. Jefferies Group LLC reiterated a “hold” rating and set a $71.00 price objective on shares of Perrigo in a research note on Wednesday, May 24th. Finally, Canaccord Genuity set a $86.00 price objective on Perrigo and gave the stock a “buy” rating in a research note on Monday, May 22nd. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $84.60.

Shares of Perrigo (NYSE:PRGO) traded up 16.36% during trading on Thursday, hitting $77.23. 8,584,425 shares of the stock traded hands. The firm’s 50-day moving average price is $73.38 and its 200-day moving average price is $72.99. The company’s market cap is $11.07 billion. Perrigo has a 52 week low of $63.68 and a 52 week high of $99.14.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, August 10th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.28. Perrigo had a positive return on equity of 11.79% and a negative net margin of 43.81%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same period in the prior year, the company posted $1.93 earnings per share. The business’s revenue for the quarter was down 7.7% compared to the same quarter last year. On average, equities research analysts anticipate that Perrigo will post $4.28 earnings per share for the current year.

WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/10/perrigo-company-prgo-given-a-93-00-price-target-at-cantor-fitzgerald.html.

Institutional investors have recently bought and sold shares of the stock. Mn Services Vermogensbeheer B.V. boosted its position in Perrigo by 4.2% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 3,824 shares of the company’s stock valued at $237,000 after buying an additional 154 shares in the last quarter. Nationwide Fund Advisors boosted its position in Perrigo by 2.3% in the first quarter. Nationwide Fund Advisors now owns 54,999 shares of the company’s stock valued at $3,651,000 after buying an additional 1,214 shares in the last quarter. Northern Capital Management LLC purchased a new position in Perrigo during the first quarter valued at about $1,334,000. Retirement Systems of Alabama boosted its position in Perrigo by 2.0% in the first quarter. Retirement Systems of Alabama now owns 69,305 shares of the company’s stock valued at $4,601,000 after buying an additional 1,348 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in Perrigo during the first quarter valued at about $214,000. Institutional investors and hedge funds own 76.38% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.